86 results about "Acute ischemia" patented technology

Methods to identify compounds that accelerate a transition of a cell from an acute hypoxic state to a hypoxic adaptive state include contacting a test compound with the cell in the acute hypoxic state, and detecting the transition of the cell from the acute hypoxic state to the cell in the hypoxic adaptive state and measuring the length of time of the transition; wherein the length of time of the transition is shorter in the presence of the test compound relative to the absence of the test compound, thereby identifying the compound that accelerates the transition of the cell from an acute hypoxic state to a hypoxic adaptive state. The compounds identified by the methods can be used to treat acute hypoxia and acute ischemia.

APRIL research shows that in a selected stroke patient, infusion of 0.2 mg / kg of ApTOLL (SEQ ID NO: 1) in combination with intravascular treatment is safe, and the death rate of 90 days is reduced. ApTOLL has proved to limit intracranial hemorrhage and reperfusion injury which may occur after recanalization, and also improve early nerve injury and long-term disability. ApTOLL molecules are provided for reducing the risk of intracranial or secondary bleeding after acute ischemic stroke, reducing nerve injury, and improving nerve recovery in a subject.

The embodiment of the invention provides a cerebral apoplexy focus detection and scoring method and device based on a multi-modal medical image. The method comprises the following steps: acquiring medical images of various different modals of a suspected acute ischemic cerebral apoplexy patient; performing registration fusion and focus labeling on the medical images of different modalities based on an attention mechanism to obtain a labeled first modal image; training a target detection model of a YOLOv8 framework based on Swin-Transform improvement by using the labeled first modal image, and carrying out target detection on the to-be-detected image based on the trained target detection model to obtain an infarction region detection result; training a semantic segmentation model by using the labeled ASPECT scoring and partitioning brain atlas, performing scoring region segmentation on the to-be-detected image based on the trained semantic segmentation model, and outputting the ASPECT scoring and partitioning brain atlas; and mapping the infarct area detection result to the ASPECT score partition brain map, and calculating to obtain an ASPECT score.

The invention discloses a pharmaceutical composition which comprises anisodine or salt thereof and 2-borneol or related substances thereof. The pharmaceutical composition provided by the invention has a synergistic effect in treatment of cardia-cerebrovascular diseases, especially central nervous diseases such as acute ischemic stroke, can effectively improve the effect of patients with cerebrovascular diseases, especially central diseases such as acute ischemic stroke, and improves the quality of life.

The invention discloses an early recognition and early warning system for acute ischemic stroke symptoms, and relates to the technical field of health detection. Comprising an image acquisition module, a voice acquisition module, a data processing module, a display module and an alarm module, the voice acquisition module is used for acquiring user audio signals; the data processing module is used for processing the collected signals to generate corresponding face judgment signals, limb judgment signals and audio judgment signals; the display module is used for displaying sentences needing to be read by the user; and the alarm module is used for judging whether the user has an acute ischemic stroke early symptom or not according to the face judgment signal, the limb judgment signal and the audio judgment signal, and if so, dialing 120 and a contact person through the mobile phone. The method can significantly improve the early warning and prevention efficiency of cerebral apoplexy, is expected to play a greater role in the field of cerebral apoplexy prevention and treatment, and improves the prognosis and life quality of patients.

The invention relates to the technical field of artificial intelligence, in particular to an acute ischemic stroke infarction core area expansion risk prediction system, which comprises an acquisition module for acquiring head MRI-DWI images and clinical information of a patient; the first prediction module is used for predicting the expansion risk of an infarction core region according to the clinical information and the head MRI-DWI image; and the second prediction module is used for marking an expanded area of the infarction core area according to the head MRI-DWI image. In order to solve the problem that an image processing scheme in the prior art is low in diagnosis efficiency improvement, two models are introduced to effectively process multi-modal information composed of a head MRI-DWI image of a patient and clinical information, the possibility of further progression of the condition of the patient according to the current multi-modal information is predicted, and the probability of further progression of the condition of the patient according to the current multi-modal information is predicted. When the infarction core area is expanded, the range is possibly expanded on the image, and the prediction range and the quantitative evaluation result of the infarction core area are visually displayed on the primary diagnosis MRI-DWI sequence, so that a doctor can make further diagnosis conveniently.

The invention relates to a stroke prognosis prediction model training method based on quantum computing and artificial intelligence, and relates to the technical field of prognosis effect prediction. According to the method, leukocyte community parameters are introduced into an acute ischemic stroke prognosis model for the first time, morphological function characteristics of leukocytes are detected through a flow cytometry, and compared with traditional inflammation indexes, the leukocyte prognosis model has higher sensitivity and objectivity and becomes an important index for predicting neurological function impairment; the indexes closely related to cerebral apoplexy prognosis are screened out through quantum calculation for the first time, and a new thought is provided for high-dimensional data feature screening; meanwhile, by comparing 14 traditional machine learning, integrated learning and deep learning models, it is judged that the LightGBM model is an acute ischemic stroke prognosis prediction model, and compared with the prior art, the LightGBM model is remarkably improved.

The invention provides a method for verifying the protective effect of a semen descurainiae water extract on myocardial injury, so as to evaluate the pharmacodynamic effect of the semen descurainiae water extract on heart failure induced by three inducements of acute ischemia-reperfusion injury, pathological cell hypertrophy and chronic hypoxia. The method comprises the following steps: respectively constructing a hiPSC-CMs-based myocardial acute ischemia reperfusion injury model, a pathological fat myocardial injury model and a chronic hypoxic myocardial injury model, and after the myocardial injury models are established, adding a descurainia seed aqueous extract and a positive control drug for intervention. And detecting corresponding indexes to verify the effect of the descurainia seed water extract on three types of heart failure. The result shows that the semen descurainiae water extract can generate a treatment effect on myocardial injury caused by chronic hypoxia by regulating and controlling the steady state of energy metabolism, inhibiting oxidative stress cascade reaction and other mechanisms.

The invention relates to the technical field of data processing, in particular to an acute ischemic stroke prognosis evaluation method and system.The method comprises the steps that the average CT value, obtained based on an ASPECTS scoring system, of an ischemic area and the average CT value, obtained based on the ASPECTS scoring system, of a normal area on the opposite side are obtained; determining a first ASPECTS-NWU value based on the average CT value of the ischemic region and the average CT value of the normal region; the ASPECTS-NWU value represents the injury degree of the ischemic area; a second ASPECTS-NWU value obtained through follow-up visit CT is obtained, and an NWU difference value is determined based on the first ASPECTS-NWU value and the second ASPECTS-NWU value; the NWU difference represents the progress of lesion edema; constructing a regression model based on the NWU difference value, and performing acute ischemic stroke prognosis evaluation based on the regression model; according to the invention, the efficiency of prognosis evaluation of acute ischemic stroke can be improved.

A method or use for managing one or more acute ischemic events. The method can include determining criteria of a clot; classifying the clot based on the criteria and generating a classification; determining an individualized treatment protocol for the clot based on the classification, the individualized treatment protocol comprising one or more techniques selected from using aspiration, restoring perfusion using a first reperfusion device, and / or restoring perfusion using a second reperfusion device; and treating the clot based on the individualized treatment protocol.

The invention relates to the technical field of intelligent disease prediction, in particular to a cerebral apoplexy postoperative vascular recanalization effect prediction method and system based on multiple modalities, and the method comprises the steps: obtaining clinical information and NCCT images of a patient; preprocessing the clinical information to obtain clinical modal features; preprocessing the NCCT image to obtain a denoised NCCT image; inputting the denoised NCCT image into a deep convolutional neural network to obtain modal features of the NCCT image; performing comparative learning according to the clinical modal features and the NCCT image modal features, and constructing a comparative loss function to obtain comparative learning loss; fusing the NCCT image modal features and the clinical modal features to obtain fused modal features, and calculating the loss of the fused modal features; and calculating dynamic total loss, and outputting a prediction result of vascular recanalization after thrombus extraction of the acute ischemic stroke patient. According to the method, accurate prediction of the effectiveness of postoperative vascular recanalization is realized through mechanisms such as deep neural network feature extraction, multi-head cross attention and comparative learning.

The invention discloses a bionic nano system for treating acute ischemic stroke and application of the bionic nano system. According to the preparation method disclosed by the invention, the TNK-DNaseI (at) ZIF-8 nano-particles are prepared by loading the ZIF-8 with the TNK-DNaseI (at) ZIF-8 and then the TNK-DNaseI (at) ZIF-8 nano-particles are coated with the natural platelet membrane, so that the TNK-DNaseI (at) ZPM bionic nano-system is prepared. The bionic nano system can achieve efficient thrombolysis, obviously reduce the infarct area, improve neurological impairment and reduce bleeding complications. The invention provides a new drug choice for treating the acute ischemic stroke, and has a wide application prospect in the aspects of clinically treating the acute ischemic stroke and improving the prognosis of a patient with the acute ischemic stroke.

The invention relates to 4 serum peptide patterns for diagnostics of intracranial hemorrhagic stroke (ICH) in humans and differential diagnosis from acute ischemic stroke that are defined using a list of the 34 quantitative peptides that in sera of patients with ICH are increased 2 folds or more as compared with individuals without stroke and patients with acute ischemic stroke and a list of 16 qualitative peptides detectable in sera of the patients with ICH but not detectable in the sera of individuals without stroke and in sera of patients with acute ischemic stroke.

The invention belongs to the technical field of biological medicine. More specifically, the invention provides the annular RNACircMAP2, and the sequence of the annular RNACircMAP2 is as shown in SEQ ID NO. 1 or SEQ ID NO. 2. The invention proves that CircMAP2 can be used as a novel biomarker for diagnosing acute ischemic stroke for the first time. Compared with a traditional imaging diagnosis method, the acute ischemic stroke can be diagnosed by detecting the expression level of the CircMAP2 in the plasma and the plasma exosome of the patient, the cerebral infarction area of the acute ischemic stroke can be speculated through the expression level of the CircMAP2, and the method has the advantages of being easy and convenient to operate, high in detection speed and low in cost; the system is especially suitable for popularization and use in primary medical institutions. The product for diagnosing acute ischemic stroke provided by the invention can quickly and accurately diagnose acute ischemic stroke, and has good clinical popularization prospect and application value.

In MRI examinations of patients with acute ischemic stroke, it is often difficult for patients to fix and hold their heads due to impaired consciousness or limb weakness. Therefore, this invention provides a tool that is structurally rational, easy to operate, and effectively enhances the head fixation effect. [Solution] A tool to support MRI examination, comprising a base 1, a head rest member 2 with adjustable anterior-posterior position, a lateral limiting member 3 with an elastic buffer layer, and an adjustment mechanism 4. The head rest member slides relative to the base to adapt to the length of the patient's neck. The lateral limiting member is biased inward by a compression coil spring and flexibly holds both sides of the head with an elastic buffer layer, absorbing and suppressing involuntary movements. The adjustment mechanism uses a single reverse-threaded adjustment rod to synchronously and symmetrically move the left and right limiting plates, enabling precise adjustment according to the head circumference. This effectively limits multi-directional micro-movements of the head during imaging and improves image stability.

Compositions comprising Lumbricus terrestris erythrocruorin (LtEc) as an oxygen carrier for use in transfusion and organ perfusion are provided. In particular, methods of using acellular compositions comprising LtEc as a universal blood substitute for transfusion of patients are provided. The methods also include ex vivo perfusion of an organ or tissue with an oxygenated acellular perfusate comprising LtEc as an oxygen carrier. Additionally, methods are provided for using compositions comprising LtEc in treatment of acute ischemia and hyperbaric oxygen therapy.

The invention discloses a traditional Chinese medicine composition for treating acute myocardial infarction, a pharmaceutical preparation and application thereof and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from, by weight, 9-18 parts of ginseng, 3-6 parts of pseudo-ginseng, 9-18 parts of ligusticum wallichii, 12-24 parts of radix achyranthis bidentatae, 6-12 parts of fructus forsythiae and 9-18 parts of radix curcumae. Compared with the prior art, the traditional Chinese medicine composition disclosed by the invention has the beneficial effects that (1) the traditional Chinese medicine composition provided by the invention can reduce the myocardial infarction area after ischemia, inhibit myocardial fibrosis and improve heart structure and function changes caused by acute ischemic injury; and (2) the traditional Chinese medicine composition provided by the invention can effectively inhibit oxidative stress reaction and relieve mitochondrial injury, thereby playing a role in protecting the heart. And (3) the traditional Chinese medicine composition has the advantage of good safety and can be taken for a long time.

The present invention relates to a traditional Chinese medicine composition for treating stroke. The traditional Chinese medicine composition is prepared from 10 - 30 parts by weight of Poria cocos, 5 - 25 parts by weight of Uncaria rhynchophylla, 5 - 25 parts by weight of Salvia miltiorrhiza, 3 - 18 parts by weight of Citrus reticulata Blanco, 3 - 18 parts by weight of Gastrodia elata Blume, 3 - 18 parts by weight of Ligusticum chuanxiong Hort., 3 - 18 parts by weight of Pinellia ternata (Thunb.) Breit., 1 - 15 parts by weight of Arisaema cum Bile, and 1 - 15 parts by weight of Carthamus tinctorius L. The traditional Chinese medicine composition of the present invention resolves phlegm and extinguishes wind, promotes blood circulation and dredges collaterals, has high safety, and has remarkable curative effects on treating stroke, especially acute ischemic stroke.

The present invention is directed to a method of treating acute ischemic stroke in a human comprising administering one of more low doses of DC009, wherein the dose is about 0.01-0.075 mg / kg / dose. The low dose administration is safe and effective in treating acute ischemic stroke in a human subject.

The invention belongs to the technical field of biology, and particularly relates to application of Lnc-PLBD1-AS1 and MCEMP1 as prognosis biomarkers of acute ischemic stroke. According to the application disclosed by the invention, it is found that the expression levels of baseline Lnc-PLBD1-AS1 and MCEMP1 of people who are dead within one year after an acute cerebral arterial thrombosis patient is attacked are obviously higher than those of survival patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of death of the acute cerebral arterial thrombosis patient within one year after the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient is attacked by the acute cerebral arterial thrombosis patient; the expression levels of the baselines Lnc-PLBD1-AS1 and MCEMP1 of people suffering from the adverse function outcome (death or severe disability) of acute cerebral arterial thrombosis patients after attack for 3 months are obviously higher than those of other patients, and the Lnc-PLBD1-AS1 and MCEMP1 have good prediction efficiency for evaluating the risk of the adverse function outcome of the acute cerebral arterial thrombosis patients after attack for 3 months.

Described are methods and systems for transcervical access of the cerebral arterial vasculature and treatment of cerebral occlusions, including ischemic stroke. The methods and devices may include methods and devices which may provide aspiration and passive flow reversal, those which protect the cerebral penumbra during the procedure to minimize injury to brain, as well as distal catheters and devices to remove an occlusion. The methods and devices that provide passive flow reversal may also offer to the user a degree of flow control. Devices and methods which provide a way to securely close the access site in the carotid artery to avoid the potentially devastating consequences of a transcervical hematoma are also described.

Disclosed in the present invention is a pharmaceutical composition, comprising anisodine or a salt thereof and 2-borneol or a related substance thereof. The pharmaceutical composition provided in the present invention exhibits synergistic effects in the treatment of cardiovascular and cerebrovascular diseases, particularly central nervous system diseases such as acute ischemic stroke, and can effectively improve outcomes of patients with cerebrovascular diseases, particularly central nervous system diseases such as acute ischemic stroke, thereby enhancing the quality of life of the patients.

The invention provides application of a product for supplementing Lrrc52 in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, and belongs to the technical field of biological medicine. The invention provides an application of a product for supplementing Lrrc52 as a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, Lrrc52 protein is supplemented into a body, so that the apoptosis and necrosis degree of myocardial cells after myocardial ischemia-reperfusion can be effectively relieved, the pathological ventricular remodeling process is restrained, the cardiac fibrosis condition is relieved, the cardiac function is enhanced, and the myocardial ischemia-reperfusion injury can be prevented and treated. And therefore, heart-related diseases such as acute ischemia-reperfusion injury, pathological ventricular remodeling and heart failure can be prevented and treated. The invention clearly reveals the potential of overexpression Lrrc52 in the aspect of improving myocardial ischemia reperfusion injury for the first time, opens up a brand new drug research and development road and an action target for prevention and treatment of the disease, and shows extremely high medicinal value and significance.

The invention relates to the technical field of biology, in particular to a method for modular assembly of artery blood vessel type organs and construction of tissue microcirculation of the artery blood vessel type organs. The method comprises the following steps: inducing human pluripotent stem cells to differentiate through a mesoderm stage to form an arterial specific vascular organoid module (AVO), and then carrying out modular assembly on the AVO in vivo or in vitro so as to quickly reconstruct a tissue microcirculation network with arterial characteristics. The obtained artery blood vessel organoid is uniform in form, the diameter of the artery blood vessel organoid is intensively distributed at about 200 microns, SOX17 and CXCR4 artery endothelial markers are expressed at the same time, and the artery blood vessel organoid has polarity and a complete basilar membrane. Transplanting experiments show that the organ can be integrated with host blood vessels in a short time, and ischemic tissue blood perfusion is recovered. The defects that existing organoid is irregular, difficult to splice, delayed in perfusion and the like are overcome, and a new strategy is provided for revascularization and acute ischemic disease repair.

A metal medicine expansion balloon without blocking blood flow comprises an adjustable inner conveying system and a screw-in type outer conveying system, the adjustable inner conveying system is formed by connecting a supporting balloon with an adjustable handle through an inner pushing rod, the screw-in type outer conveying system is arranged on the periphery of the adjustable inner conveying system, and the screw-in type outer conveying system is connected with the adjustable handle through an outer pushing rod. Comprising a covered stent, a drug coating film, a main body skeleton, an outer pushing rod and a screw-in valve, the drug coating film covers the main body skeleton through the covered stent, the near end of the covered stent is connected with the far end of the outer pushing rod, and the near end of the outer pushing rod is connected with the far end of the screw-in valve. The internal system and the external system work cooperatively, a multi-channel blood flow path is formed during expansion, intraoperative blood perfusion is kept, acute ischemia and thrombosis risks during the operation are reduced, the internal supporting balloon adopts a shape memory alloy weaving process, pressure feedback in the expansion process is more obvious, the adherence gap is smaller, the adherence process is conformal, and the system is more suitable for complex lesions; meanwhile, the cutting effect is achieved, and the expansion effect is effectively improved.

The application discloses application of a 2-amino-pyrazine derivative in preparation of a medicine for treating and / or preventing apoplexy and complications, wherein the 2-amino-pyrazine derivative iMAP4K1 is (R)-4-[5-amino-6-[[1-(1-methyl-4-piperidyl)-4-pyrazolyl]oxy]-2-pyrazinyl]-N-[2-(3-fluoro-1-pyrrolidinyl)ethyl]-2,6-dimethylbenzamide; the apoplexy is acute ischemic stroke; and the 2-amino-pyrazine derivative can be used as an active ingredient in a medicine for treating and / or preventing post-stroke brain injury and complications, effectively reducing post-stroke cerebral infarction volume, improving sensory-motor and balance nerve functions, and preventing and treating post-stroke complications such as cerebral edema and acute lung injury.

The invention discloses a traditional Chinese medicine monomer nanoparticle oral delivery system based on intestinal liver circulation and a preparation method thereof, spherical nanoparticles (SA NPs) with the particle size of 194 + / -20 nm are formed through self-assembly of threat resin acid (SA), and the limitation of a traditional nano carrier is broken through: the oral bioavailability reaches 34.7% by utilizing an ASBT-mediated intestinal liver circulation mechanism; the gastric acid environment is tolerated (the pH is stable at 1.5), and after penetrating through the intestinal epithelium, the drug is targeted to ischemic brain tissues; the medicine has carrier-medicine dual functions, and the cerebral infarction volume is reduced by 34.1% when the medicine is singly used; after the neuroprotective peptide NA1 is loaded (the drug loading capacity is 5.8 wt%), the infarct volume is reduced by 68.7% through synergism. The system is suitable for pre-hospital first aid of cerebral apoplexy, and the freeze-dried powder can be stored at normal temperature for 12 months. The delivery system has a great application prospect in preparation of drugs for treating acute ischemic stroke needing rapid brain targeting.

The present invention discloses the use of a compound in the preparation of a medicament for treating and / or preventing stroke. The compound is 2,3-dihydronaphtho[1,2-b]furan-4,5-dione, and the stroke includes acute ischemic stroke or ischemic reperfusion brain injury. The compound can effectively treat or prevent acute ischemic stroke by alleviating the acute brain injury caused by acute ischemic stroke or ischemic reperfusion, reducing the volume of cerebral infarction after acute ischemic stroke, alleviating cerebral edema after stroke, and improving neurological function after stroke.